CN119390667A - 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 - Google Patents

四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 Download PDF

Info

Publication number
CN119390667A
CN119390667A CN202411518463.7A CN202411518463A CN119390667A CN 119390667 A CN119390667 A CN 119390667A CN 202411518463 A CN202411518463 A CN 202411518463A CN 119390667 A CN119390667 A CN 119390667A
Authority
CN
China
Prior art keywords
anavex19
anavex2
further characterized
disease
scf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411518463.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·约克
L·A·伦纳德
D·M·莱杰
L·S·丹特里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Publication of CN119390667A publication Critical patent/CN119390667A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CN202411518463.7A 2015-07-22 2016-07-19 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 Pending CN119390667A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562195486P 2015-07-22 2015-07-22
US62/195,486 2015-07-22
PCT/IB2016/001181 WO2017013498A2 (en) 2015-07-22 2016-07-19 Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
CN201680033152.9A CN108026059A (zh) 2015-07-22 2016-07-19 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680033152.9A Division CN108026059A (zh) 2015-07-22 2016-07-19 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Publications (1)

Publication Number Publication Date
CN119390667A true CN119390667A (zh) 2025-02-07

Family

ID=57833871

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411518463.7A Pending CN119390667A (zh) 2015-07-22 2016-07-19 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
CN201680033152.9A Pending CN108026059A (zh) 2015-07-22 2016-07-19 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680033152.9A Pending CN108026059A (zh) 2015-07-22 2016-07-19 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物

Country Status (7)

Country Link
US (4) US10413519B2 (enExample)
EP (2) EP3325456B1 (enExample)
JP (3) JP7304043B2 (enExample)
CN (2) CN119390667A (enExample)
CA (1) CA2986349A1 (enExample)
HK (1) HK1247926A1 (enExample)
WO (1) WO2017013498A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315375A (zh) * 2017-06-14 2020-06-19 阿纳韦克斯生命科学公司 用于治疗阿尔茨海默病的anavex2-73
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
WO2019200345A1 (en) * 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
EP4520842A3 (en) 2018-05-18 2025-09-10 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
US12473268B2 (en) 2020-02-04 2025-11-18 Assia Chemical Industries, Ltd. Solid state forms of Blarcamesine salts
WO2023208133A1 (zh) 2022-04-29 2023-11-02 苏州科睿思制药有限公司 布拉美森盐酸盐的晶型及其制备方法和用途
US12018005B1 (en) * 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
GR1002616B (el) 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GR1006794B (el) * 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
GB201005623D0 (en) * 2010-04-01 2010-05-19 Vantia Ltd New polymorph
GR1007686B (el) 2011-07-08 2012-09-12 Αλεξανδρος Δημητριου Βαμβακιδης Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
GR1008233B (el) 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
EP3324956B1 (en) 2015-07-22 2024-11-20 Anavex Life Sciences Corp. Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
EP4616852A3 (en) 2025-10-22
US10966952B2 (en) 2021-04-06
US11661405B2 (en) 2023-05-30
JP7304043B2 (ja) 2023-07-06
JP2018524307A (ja) 2018-08-30
EP4616852A2 (en) 2025-09-17
US10413519B2 (en) 2019-09-17
US20230278973A1 (en) 2023-09-07
EP3325456A4 (en) 2019-01-23
CN108026059A (zh) 2018-05-11
US20180169060A1 (en) 2018-06-21
EP3325456A2 (en) 2018-05-30
WO2017013498A3 (en) 2017-03-02
HK1247926A1 (zh) 2018-10-05
JP2023083528A (ja) 2023-06-15
US20210220321A1 (en) 2021-07-22
US20190350892A1 (en) 2019-11-21
WO2017013498A2 (en) 2017-01-26
EP3325456B1 (en) 2025-09-03
JP2021073300A (ja) 2021-05-13
JP7492781B2 (ja) 2024-05-30
CA2986349A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
JP7492781B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物
Cui et al. Naringenin cocrystals prepared by solution crystallization method for improving bioavailability and anti-hyperlipidemia effects
CN113527203B (zh) 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CN101768199B (zh) 醋酸阿比特龙的多晶型物及其制备方法
JP2018511580A (ja) イブルチニブの多形体
Raza et al. Preparation, characterization, and in vitro anti-inflammatory evaluation of novel water soluble kamebakaurin/hydroxypropyl-β-cyclodextrin inclusion complex
Liu et al. Development of nimesulide amorphous solid dispersions via supercritical anti-solvent process for dissolution enhancement
Cheng et al. Micronization of etoposide using solution-enhanced dispersion by supercritical CO2
JP6126040B2 (ja) ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途
WO2015052568A2 (en) Solid forms of curcumin and derivatives thereof
Rodrigues et al. New thermoresistant polymorph from CO2 recrystallization of minocycline hydrochloride
CN106146498A (zh) 一种新的利格列汀化合物
Mondal et al. Insight into the formation of heteromolecular hydrogen bonds between dasatinib and GRAS molecules
WO2015046489A1 (ja) スプレードライ法を用いたＤ－マンニトールα型結晶の選択的製造方法
CN107226784B (zh) 超临界反溶剂造粒技术制备扑热息痛与甜菜碱共晶的方法
CN106336363A (zh) 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN104513201B (zh) 马来酸匹杉琼的结晶
CN105906540B (zh) 化合物及其制备方法和应用
WO2015170827A1 (ko) 실로도신 감마형 결정의 제조방법
JP7486763B2 (ja) 安定なアジルサルタン微細結晶の製造方法
CN109476690A (zh) 结晶铂基化合物
CN108558855A (zh) 一种三嗪类盐酸盐化合物的晶型
CN108285446A (zh) 一种三嗪类化合物的晶型
CN101384584A (zh) 贝西吡啶盐酸盐的晶型、制备方法及其应用
EP2749557A1 (en) Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40121350

Country of ref document: HK